Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (NCT07224529) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
United States48 participantsStarted 2026-05-01
Plain-language summary
This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes.
If you join the study, after a short "run-in" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland function will be assessed. The goal is to learn whether Vevye improves symptoms (like eye dryness or irritation) and signs (such as changes on the eye's surface or lid margins) of MGD.
You will also be monitored for safety and comfort of the eye drop. The information obtained from this study may help determine whether this treatment is beneficial for people with this condition and contribute to future care options. Participation is voluntary and you may stop at any time.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \> 18 years
✓. VAS Dryness \> 70
✓. Posterior lid margin hyperemia grade 2 or worse for both eyes
✓. Corneal fluorescein staining \> 6 (NEI scale) for at least one eye
✓. Modified meibomian gland expression score ≥ 23 for both eyes OR ≥ 7 for expressible glands for both eyes OR a combination of the two
✓. Unanesthetized Schirmer ≥ 5 mm in 5 minutes for both eyes
Exclusion criteria
✕. Age \> 18 years
✕. VAS Dryness \> 70
✕. Posterior lid margin hyperemia grade 2 or worse for both eyes
✕. Corneal fluorescein staining \> 6 (NEI scale) for at least one eye
✕. Modified meibomian gland expression score ≥ 23 for both eyes OR ≥ 7 for expressible glands for both eyes OR a combination of the two
What they're measuring
1
Change in Meibomian Gland Expressibility Score
Timeframe: Baseline to Week 24 (±1 week)
2
Change in Visual Analog Scale (VAS) Dryness Score
Timeframe: Baseline to Week 24 (±1 week)
3
Change in Corneal Fluorescein Staining (NEI Scale)